当前位置:首页 > 报告详情

阿斯利康-JPM-2025-presentation.pdf

上传人: c** 编号:604009 2025-02-03 26页 1.48MB

1、JP Morgan Healthcare ConferenceAradhana Sarin,EVP&CFO14 January 20252Forward looking statementsIn order,among other things,to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act of 1995,AstraZeneca(hereafter the Group)provides the following cautionary statement:Thi

2、s document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group,including,among other things,statements about expected revenues,margins,earnings per share or other financial or other measures.Although the Group believes its expec

3、tations are based on reasonable assumptions,any forward-looking statements,by their very nature,involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.The forward-looking statements reflect knowled

4、ge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements.The Group identifies the forward-looking statements by using the words anticipates,believes,expects,intends and similar expressions in such state

5、ments.Important factors that could cause actual results to differ materially from those contained in forward-looking statements,certain of which are beyond the Groups control,include,among other things:the risk of failure or delay in delivery of pipeline or launch of new medicines;the risk of failur

6、e to meet regulatory or ethical requirements for medicine development or approval;the risk of failures or delays in the quality or execution of the Groups commercial strategies;the risk of pricing,affordability,access and competitive pressures;the risk of failure to maintain supply of compliant,qual

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
AstraZeneca PLC在2025年1月14日JP摩根医疗保健会议上发布了其财务和业务情况。主要内容包括: 1. 财务数据:2024年前9个月总收入为61.29亿美元,同比增长19%;核心每股收益为3.92美元,同比增长11%。 2. 业务发展:公司重点关注五大治疗领域,包括肿瘤生物制药、罕见病、呼吸与免疫学、疫苗与免疫疗法、心血管、肾脏与代谢。2024年前9个月,这五大领域的总收入为57.5亿美元,同比增长22%。 3. 研发进展:公司有21种新分子实体(NMEs)处于后期开发阶段,预计到2030年将推出20种NMEs。2025年将有7种NMEs的首次三期试验数据公布。 4. 环境与社会责任:公司致力于减少碳排放,自2015年以来,绝对范围1和2排放量减少了68%。公司还致力于性别平等,目标是在2025年管理层中实现性别平等。 5. 未来展望:公司预计到2030年,总收入将达到800亿美元,核心运营利润率将达到35%以上。
请问AstraZeneca在2025年有哪些新药上市计划? AstraZeneca如何通过创新技术推动2030年后的增长? AstraZeneca在健康公平和可持续发展方面有哪些举措?
客服
商务合作
小程序
服务号
折叠